Table 2 Baseline and disease characteristics for randomized, evaluable patients
Characteristic | Arm A (cetuximab alone) | Arm B (cetuximab + pemetrexed) |
|---|---|---|
|  | N = 20 | N = 23 |
Age (years) | Â | Â |
Median | 62 | 55 |
Range | (36–76) | (45–75) |
Sex: No. (%) | Â | Â |
Men | 14 (70) | 13 (57) |
Women | 6 (30) | 10 (43) |
Ethnicity: No. (%) | Â | Â |
White | 13 (65) | 17 (74) |
African-American | 7 (35) | 5 (22) |
Asian | 0 (0) | 1 (4) |
Smoking history: No. (%) | Â | Â |
Current | 7 (35) | 6 (26) |
Past | 11 (55) | 13 (57) |
Never | 2 (10) | 2 (9) |
Unknown | 0 (0) | 2 (9) |
Histology: No. (%) | Â | Â |
Unspecified | 7 (35) | 9 (39) |
Squamous | 6 (30) | 8 (35) |
Adenocarcinoma | 7 (35) | 6 (26) |